Bukwang Pharm acquires joint license of Meditoxin Inj for treatment purpose from Eisai

Bukwang Pharm announced that it signed a co-marketing and distribution agreement with Eisai Korea for the co-sales and exclusive distribution license of ‘Meditoxin Inj 200 Units,’ a medical botulinum injection, in Korea.

The owner of Meditoxin Inj 200 Units is Meditox. So far, Eisai Korea had been distributed and sold with the exclusive license in Korea from Meditox. Under the agreement, Eisai...